Gliptins linked to arthralgia, FDA warns

DPP-4 inhibitor drugs for type 2 diabetes may cause severe and disabling arthralgia, the FDA has warned, though Australian specialists say it is a rare adverse event.

The US regulator has added a warning about severe joint pain to the labels of gliptins after receiving 33 reports of the adverse effect associated with their use.

The joint pain was severe enough to be disabling and occurred anything from